LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED

Their core work

Labcorp (formerly Covance) is a major contract research organization (CRO) providing preclinical and early-phase clinical development services to the pharmaceutical and biotech industries. Within H2020, they contribute toxicology expertise, nonclinical safety assessment, and pharmacovigilance capabilities to large health-focused consortia. Their role centers on evaluating drug safety — from computational immunotoxicology modeling to real-world pregnancy medication safety monitoring — acting as the industry bridge between laboratory science and regulatory compliance.

What they specialise in

How they've shifted over time

Their early H2020 work (2017-2018) centered on advanced drug formulation — liposomal nanocarriers, cellular membrane penetration, and GMP manufacturing for rare disease therapy (Fabry disease). From 2019 onward, they shifted decisively toward safety science and real-world evidence: pharmacovigilance in pregnancy, computational immunotoxicology, and big-data-driven clinical evidence generation. This reflects the broader pharmaceutical industry pivot from traditional lab-based preclinical testing toward in-silico models, micro physiological systems, and population-level safety monitoring.

Labcorp is moving toward computational and data-driven safety assessment methods, making them a strong partner for projects replacing animal testing with in-silico and organ-on-chip approaches.

How they like to work

Labcorp exclusively participates as a partner, never as coordinator — consistent with their CRO business model where they provide specialized services within larger research programs. With 148 unique partners across 25 countries in just 5 projects, they operate in very large IMI-style consortia (typically 30+ partners). This means they are comfortable in complex multi-stakeholder environments and bring industry-grade processes, but prospective partners should expect a contributor role rather than a project driver.

Despite only 5 projects, Labcorp has built connections with 148 unique partners across 25 countries — a remarkably wide network driven by participation in large public-private IMI consortia. Their reach spans most of the EU, with no narrow geographic concentration.

What sets them apart

As a global CRO with deep regulatory and preclinical expertise, Labcorp brings something most academic or SME partners cannot: industry-standard GLP/GMP compliant testing infrastructure and direct experience with regulatory submission pathways. Their combination of traditional toxicology with emerging computational immunology and micro physiological systems positions them at the transition point between old and new safety assessment methods. For consortium builders, they offer credibility with regulators and pharma companies that few academic partners can match.

Highlights from their portfolio

• imSAVAR
  Addresses the critical challenge of predicting immune-related adverse effects of immunotherapies using computational models and micro physiological systems — directly relevant to the ongoing replacement of animal testing.
• Smart-4-Fabry
  Their only funded project (EUR 434,395), developing a multifunctional nanoformulation for the rare disease Fabry — shows capability in advanced drug delivery and GMP manufacturing.
• ConcePTION
  Large-scale pharmacovigilance ecosystem for medication safety in pregnancy — a critically underserved area where Labcorp contributes predictive modeling and biobank expertise.